The decisions made at the Greater Manchester Medicines Management Group (GMMMG) October 2023 meeting have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/. This includes the recommendations made by GMMMG in October 2023 and NICE Technology appraisals published in June 2023.
The following decisions were approved and can be found at:
- Updates to formulary and RAG list – https://gmmmg.nhs.uk/joint-formulary/gmmmg-formulary-chapters/ and https://gmmmg.nhs.uk/rag-category/adult/
- Commissioning statement: Unlicensed use of omalizumab for severe chronic inducible urticarias –
- High Cost Drugs Inflammatory Bowel Disease pathway – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
- Long-Term Azithromycin in Adults with Chronic Respiratory Disease: Guidance for Primary Care – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
Please could you disseminate for implementation within your organisations.
Drugs with a NICE recommendation published in July have been considered by CRG at its October 2023 meeting, and will be considered for approval by GMMMG and CEGC at their November 2023 meetings. All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.